Schmidmaier et al. have already reported that the Mev pathway and the downstream RhoA/RhoA kinase signaling pathway mediate SC-induced MDR, and that targeting of this pathway by SIM may improve the efficacy of anti-myeloma therapies by reduction of SC-induced MDR [39]. The gene discussed is RHOA; the disease is plasma cell myeloma.